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Tbjective: We sought to assess determinants of clinical decision making in patients
ith stable coronary artery disease.
ethods: The 2936 patients with stable angina pectoris who enrolled in the Euro
eart Survey on Coronary Revascularization were the subject of this analysis. After
he diagnosis has been confirmed, physicians decided on treatment: medical man-
gement or revascularization therapy by means of percutaneous coronary interven-
ion or coronary bypass surgery. We applied logistic regression analyses to evaluate
he relation between baseline characteristics and treatment decision: medical treat-
ent versus percutaneous coronary intervention, medical treatment versus coronary
ypass surgery, and percutaneous coronary intervention versus coronary bypass
urgery.
esults: The median age was 64 years, 77% were men, and 20% had diabetes.
edical therapy was intended in 690 (24%) patients, percutaneous coronary inter-
ention in 1503 (51%) patients, and coronary bypass surgery in the remaining 743
25%) patients, respectively. Revascularization was generally preferred in patients
ith more severe anginal complaints, an intermediate-to-large area of myocardium
t risk, and preserved left ventricular function who had not undergone prior coronary
evascularization, provided lesions were suitable for treatment. Coronary bypass
urgery was preferred over percutaneous coronary intervention in multivessel or left
ain disease, as well as in those with concomitant valvular heart disease, provided
sufficient number of lesions were suitable for coronary bypass surgery. In those
ith previous coronary bypass surgeries, more often percutaneous coronary inter-
ention was preferred than redo coronary bypass surgery. Diabetes was not asso-
iated with more frequent preference for coronary bypass surgery.
onclusions: In the hospitals that participated in the Euro Heart Survey on Coronary
evascularization, treatment decisions in stable coronary artery disease were largely
n agreement with professional guidelines and determined by multiple factors. Most
mportant deviations between guideline recommendations and clinical practice were
een in patients with extensive coronary disease, impaired left ventricular function,
nd diabetes.
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A
CDn the Western world stable coronary disease is a com-
mon and disabling disorder. Treatment aims to mini-
mize or abolish symptoms, to prevent disease progres-
ion, and to improve prognosis by reducing the risk of
yocardial infarction or death. According to current treat-
ent guidelines, patients should receive cardioprotective
harmacotherapy, including antiplatelet, antithrombotic,
nd lipid-lowering agents, as well as antianginal medica-
ion. In selected patients coronary revascularization by
eans of either percutaneous coronary intervention (PCI) or
oronary artery bypass grafting (CABG) might be appropri-
te. In the absence of symptomatic indication, revascular-
zation is recommended in patients with left main disease,
ultivessel disease, significant disease of the proximal part
f the left anterior descending artery (LAD), and a fair
mount of viable myocardium at risk. CABG is preferred in
atients with diabetes, those with more extensive disease,
hose with impaired left ventricular function, and those with
natomy that is not suitable for PCI.1-11
The European Society of Cardiology realized that the
linical management of cardiac patients in daily practice
ight vary from treatment guidelines. A broad range of
linical and lesion-specific characteristics might play a role
n shaping treatment decisions in the real world. To obtain
uantitative information on the adherence to European and
nternational guidelines across member states, the European
ociety of Cardiology has launched the Euro Heart Survey
EHS) program (extensive information regarding this pro-
ram is available on the Web).12 The EHS on Coronar
evascularization (EHS-CR), which was conducted in
001-2002, with follow-up in 2003, enrolled 3006 consec-
tive patients (in 130 participating centers) with docu-
ented stable coronary disease undergoing coronary an-
iography. This well-characterized study population
rovides a unique opportunity to conduct a systematic anal-
sis of the relation between patient characteristics and
hoices about patient management.
aterials and Methods
atients
he EHS-CR has been described in detail elsewhere.12,13 Briefly,
he survey was designed to screen all consecutive patients under-
oing invasive coronary diagnostic or therapeutic procedures. Pa-
ients were enrolled if they had a stenosis diameter of at least 50%
n at least one major epicardial coronary artery. Data were then
ent to a central database in the European Heart House (Sophia
ntipolis, France) through the Web by using the Macro software
InferMed). The collected data included demographics, comorbid-
ty, diagnosis, and detailed information regarding diagnostic an-
iography and treatment modalities. Clinical outcome and compli-
ations were recorded during the initial hospitalization and at
-year follow-up. By using the applied software, data were auto-
atically checked for completeness, internal consistency, and ac-
uracy. The data management staff at the European Heart House
erformed additional edit checks. If necessary, queries were re- i
002 The Journal of Thoracic and Cardiovascular Surgery ● Novolved with the local data-collecting officers. Between November
, 2001, and March 1, 2002, a total of 5767 patients were enrolled.
ollow-up was obtained at 11 months after enrollment. The current
nalysis is limited to the 3006 (52%) patients with stable angina as
he primary diagnosis.
reatment Decisions
he EHS-CR is a descriptive study, and the survey protocol did not
ictate any treatment decision. In general physicians were encour-
ged to treat their patients in conformance with the most recent
uidelines. To be informed of the physician’s preferred and in-
ended treatment, the survey included the following question: As
he treating physician, which treatment option would be your first
hoice? According to the reply to this question, patients were
lassified with a physician’s intention for medical treatment, PCI,
r CABG.
ata Description and Data Analysis
ontinuous data are described as median values with corre-
ponding 25th and 75th percentiles, and dichotomous data are
escribed as counts and percentages. Differences in baseline
linical and angiographic characteristics in subgroups of pa-
ients according to intended treatment were analyzed by using
npaired Student t tests, analyses of variance (continuous data),
nd 2 tests (dichotomous data) as appropriate. All statistical
ests were 2 sided.
Altogether, 893 (30%) patients had missing data on at least one
f the variables that were considered as potential determinants of
reatment decisions (Table 1). Simple missing data imputation 
herefore applied by assigning the series mean value of the variable
t hand. Univariable and multivariable logistic regression analyses
ere then applied to further evaluate the relation between a broad
ange of baseline characteristics and intended treatment. Separate
egression models were developed for intended medical treatment
ersus PCI, medical treatment versus CABG, and CABG versus
CI. All variables entered the multivariable stage, irrespective of
he results of univariable analyses. The final multivariable model
as then constructed by means of backward deletion of the least
ignificant characteristics, while applying a P value of .05 as the
hreshold of significance.
The performance of the multivariable models was studied with
espect to discrimination and calibration. Discrimination refers to
he ability to distinguish patient subgroups (intended medical
reatment vs PCI, intended medical treatment vs CABG, and
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
EHS  Euro Heart Survey
EHS-CR Euro Heart Survey on Coronary
Revascularization
LAD  left anterior descending artery
PCI  percutaneous coronary interventionntended CABG vs PCI) by using the model. It was quantified by
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CDsing a measure of concordance, the c-statistic. For binary out-
omes, the c-statistic is identical to the area under the receiver
perating characteristic curve. The c-statistic lies between 0.5 and
able 1. Clinical characteristics of the study population
All
o. of patients 2936
emographics
Age, y 64 (56-71)
Male sex 77
isk factors, medical history, and medication
at admission
Current smoking 21
Diabetes mellitus (patients using insulin or
oral antidiabetic drugs)
20
Hypercholesterolemia 69
Hypertension 61
PCI 24
CABG 13
Myocardial infarction 43
Peripheral vascular disease 13
Cerebrovascular disease 8
Renal insufficiency 3
Use of -blockers, calcium antagonists, or
nitrates
None 11
Mono 36
Double 41
Triple 11
resentation
Concomitant valvular heart disease 7
NYHA symptomatic (heart failure) class
No heart failure 84
I or II 10
III or IV 5
CCS angina class
I 15
II 48
III 32
IV 5
ize of the myocardium at risk§
Small 28
Intermediate 53
Large 19
EuroSCORE 3 (2-5)
Left ventricular function¶
Normal (LVEF 50%) 66
Mild impairment (LVEF 40%-50%) 23
Moderate impairment (LVEF 30%-40%) 7
Severe impairment (LVEF 30%) 4
ontinuous data (age and EuroSCORE) are presented as median values (25
ercutaneous coronary intervention; CABG, coronary artery bypass graftin
VEF, left ventricular ejection fraction. P values: *.001, †.05, ‡.01.
merican College of Cardiology/America Heart Association guidelines.18
eveloped to quantify the risk of perioperative mortality in patients schedand is better if closer to 1. Calibration refers to whether the H
The Journal of Thoracicredicted frequencies (by using the model) of patients with a
hysician’s preference for a specific treatment modality agree with
he observed frequencies. Calibration was measured with the
Intended treatment P
valueMedical PCI CABG
690 1503 743
64 (56-71) 63 (54-70) 66 (57-72) *
75 76 80 †
17 23 21 †
22 19 21
67 71 66 †
64 60 61
27 28 12 *
24 12 4 *
49 41 40 ‡
13 11 17 *
8 6 10 †
5 4 2 †
‡
13 10 11
40 37 32
37 42 45
10 12 12
8 4 13 *
*
80 89 80
13 8 13
8 3 7
*
24 14 10
49 50 42
25 31 41
2 5 6
*
39 29 15
44 54 58
16 17 27
4 (2-6) 3 (1-5) 4 (2-6) *
*
59 71 62
23 22 26
10 5 9
8 2 3
th percentiles), and dichotomous data are presented as percentages. PCI,
HA, New York Heart Association; CCS, Canadian Cardiovascular Society;
litative estimate based on noninvasive diagnostics, as described in the
opean System for Cardiac Operative Risk Evaluation, which is a score
or cardiac surgery. ¶Based on quantitative or qualitative measurements.th-75
g; NY
§Quaosmer-Lemeshow goodness-of-fit test.14,15
and Cardiovascular Surgery ● Volume 132, Number 5 1003
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A
CDesults
atients and Intended Treatment
he intended treatment was not recorded in 70 (2.3%)
atients, leaving 2936 patients suitable for analysis. Medical
herapy was intended in 690 (24%) patients, PCI in 1503
51%) patients, and CABG in the remaining 743 (25%)
atients, respectively. Eighty-six percent of patients who
ere selected for coronary revascularization underwent this
rocedure within 1 year after initial coronary angiography.
welve percent of patients undergoing PCI were treated for
n-stent restenosis or restenosis after a prior nonstent pro-
edure. Stents were used in 74% of patients undergoing
CI. In 15% of patients undergoing CABG, coronary sur-
ery was combined with valve repair or replacement.
linical and Angiographic Characteristics
he median age of the study population was 64 years, and
7% were men. Twenty percent of patients had diabetes. A
istory of prior PCI was reported in 24% of patients, and
rior CABG was reported in 13%. Most patients had mild-
o-moderate anginal complaints and an intermediate risk
rofile. A moderately or severely impaired left ventricular
unction (left ventricular ejection fraction 40%) was ob-
erved in 11%. Thirty-four percent of patients had single-
essel disease, 57% had multivessel disease, and 9% had
eft main disease.
Important differences in relevant clinical (Table 1) 
ngiographic (Table 2) baseline characteristics were 
erved according to intended treatment. Patients in whom
he physician preferred medical therapy more often had a
istory of coronary revascularization or a history of myo-
ardial infarction than the remaining patients. Their anginal
omplaints were relatively mild, but they more often had
ymptomatic heart failure. Patients scheduled for medical
herapy had a small area of jeopardized myocardium, a high
umber of total occlusions and type C lesions, and a low
umber of lesions suitable for revascularization.
Patients scheduled for PCI were younger and less often
ad congestive heart failure than the remaining patients.
heir anginal complaints were usually moderate, whereas
nly a limited number of diseased segments was observed.
he number of total occlusions and type C lesions was low.
ompared with patients scheduled for medical treatment,
atients scheduled for PCI less often had a history of CABG
r myocardial infarction. Compared with patients scheduled
or CABG, they more often had a history of CABG but less
ften had proximal LAD or left main disease.
Patients in whom the physician preferred CABG were
lder, were more often men, and more often had peripheral
ascular disease, cerebrovascular disease, and valvular heart
isease than the remaining patients. They often had severe
nginal symptoms, a large area of myocardium at risk, and m
004 The Journal of Thoracic and Cardiovascular Surgery ● Novxtensive vessel disease. The number of lesions suitable for
CI was low.
eterminants of Intended Revascularization Versus
edical Treatment
he number of lesions suitable for PCI was the most im-
ortant determinant of intended PCI versus medical treat-
ent: a PCI was 28 times more likely in patients with at
east one lesion suitable for such an approach (Table 3)
everity of the anginal symptoms, the amount of jeopar-
ized myocardium, and left ventricular function were also
mportant determinants of the choice for PCI versus medical
reatment. Patients in Canadian Cardiovascular Society an-
inal class II to IV were 1.8 to 6.2 times more likely to undergo
CI than those in class I. Patients with an intermediate-to-
arge amount of myocardium at risk were 2.0 to 2.4 times
ore likely to undergo PCI than those with a small amount.
n contrast, patients with moderately to severely impaired
eft ventricular function were 2.6 to 3.7 times less likely to
e scheduled for PCI (odds ratio, 0.38-0.27).
The number of lesions suitable for CABG was the most
mportant determinant of intended CABG versus medical
reatment: a CABG was 5.1 to 36 times more likely in
atients with 1 to 3 or more lesions suitable for the surgical
pproach (Table 3). The severity of the anginal sympt
he amount of jeopardized myocardium, and left ventricular
unction were also important determinants of the choice for
ABG versus medical treatment. However, whether a
ABG has been performed in the past was a more decisive
actor: patients with a history of CABG were 25 to 50 times
ore likely to be scheduled for CABG.
eterminants of Intended CABG Versus PCI
n patients selected for PCI or CABG, the number of lesions
uitable for the other technique was the most dominating
actor for the final treatment choice (Table 3). A histo
ABG, the presence of left main disease, and the presence
f valvular heart disease were also important determinants
f the physician’s preference for either CABG or PCI.
iabetes and left ventricular function were not associated
ith the physician’s choice in this respect.
erformance of Predictive Models
he discriminative power of the model to separate patients
ith a physician’s preference for medical versus revascu-
arization treatment was good. The c-statistics for the PCI
ersus medical treatment and CABG versus medical treat-
ent models were 0.85 and 0.92, respectively. The Hosmer-
emeshow tests for calibration were nonsignificant (P .33
nd P  .29, respectively; Figure 1, left and middle panels),
ndicating that the models accurately predicted the proba-
ility for a patient to be selected for coronary revascular-
zation (PCI or CABG). The discriminative power of the
odel to separate patients with a physician’s preference for
ember 2006
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A
CDABG versus PCI treatment was also excellent (c-statistic
0.95). The Hosmer-Lemeshow test for calibration was
ignificant (P  .001), but the difference between the ex-
ected and observed probabilities was less than 3% in 8
atient subgroups on the basis of the deciles of the proba-
able 2. Angiographic characteristics of the study popula
All
o. of patients 2936
itral insufficiency potentially requiring
surgical intervention
14
iseased arteries
Left anterior descending 73
Proximal left anterior descending 33
Left circumflex 59
Right coronary 64
Left main 9
o. of diseased arteries
1 34
2 30
3 27
LM 9
o. of diseased segments
1 29
2 23
3 18
4 30
otal occlusions
0 59
1 26
2 9
3 6
ype C lesions
0 56
1 23
2 11
3 11
esions suitable for PCI
0 28
1 37
2 20
3 16
esions suitable for CABG
0 24
1 26
2 17
3 33
rafts with 50% diameter stenosis†
0 39
1 30
2 31
ata represent percentages. PCI, Percutaneous coronary intervention; CAB
f prior CABG only.ility distribution (Figure 1, right panel). i
The Journal of Thoraciciscussion
n this analysis of patients with stable angina and angio-
raphically significant coronary artery disease who enrolled
n the EHS-CR study, revascularization was generally pre-
erred in patients with more severe anginal complaints, an
Intended treatment P
valueMedical PCI CABG
690 1503 743
16 11 17 *
69 67 88 *
26 26 52 *
58 51 78 *
64 56 80 *
8 4 21 *
*
40 44 8
26 35 21
25 17 50
8 4 21
*
34 38 8
21 28 15
17 16 21
28 18 57
*
46 69 51
31 21 31
13 6 12
11 4 6
*
48 63 48
24 23 22
14 8 15
14 7 14
*
56 6 46
22 53 16
12 26 15
10 15 23
*
41 26 4
21 37 8
13 20 16
24 17 72
*
50 30 27
28 34 27
22 36 46
ronary artery bypass grafting. P values: *.001. †In patients with a historytion
G, contermediate-to-large area of myocardium at risk, and a
and Cardiovascular Surgery ● Volume 132, Number 5 1005
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CDable 3. Association between patient characteristics and the physician’s preference for PCI versus medical treatment,
ABG versus medical treatment, and CABG versus PCI
Intended treatment
PCI vs medical CABG vs medical CABG vs PCI
-statistic 0.85 0.92 0.95
Odds ratio
(95% CI)* 2
Odds ratio
(95% CI)† 2
Odds ratio
(95% CI)‡ 2
ge, y
60 1
60-70 0.62 (0.41-0.94) 5
70 0.42 (0.25-0.69) 12
ale sex 1.4 (1.1-1.8) 5 1.6 (1.1-2.3) 6
ypercholesterolemia 0.62 (0.45-0.85) 9
rior PCI 0.65 (0.43-0.99) 4 0.63 (0.43-0.93) 5
rior CABG
No 1 1 1
Yes, no diseased grafts 0.43 (0.27-0.70) 11 0.02 (0.01-0.05) 66 0.07 (0.02-0.22) 21
Yes, 1 diseased graft 1.5 (1.0-2.4) 3 0.04 (0.02-0.07) 86 0.02 (0.01-0.04) 88
rior myocardial infarction 0.75 (0.54-1.0) 3
enal insufficiency 0.28 (0.12-0.66) 9 0.21 (0.08-0.53) 11
oncomitant valvular heart disease 4.8 (2.7-8.4) 30 5.9 (3.7-9.9) 44
YHA symptomatic (heart failure) class
No heart failure 1
I or II 1.0 (0.62-1.6) 0
III or IV 0.46 (0.25-0.84) 6
CS angina class
I 1 1
II 1.8 (1.3-2.5) 13 1.6 (1.0-2.6) 4
III 1.8 (1.3-2.6) 11 2.4 (1.4-3.9) 11
IV 6.2 (2.7-14) 19 7.1 (2.5-20) 13
oninvasive risk stratification
Low 1 1
Intermediate 2.0 (1.6-2.7) 27 3.3 (2.2-4.9) 35
High 2.4 (1.6-3.6) 18 3.4 (2.0-5.7) 20
uroSCORE 3 0.71 (0.54-0.93) 6 2.1 (1.3-3.4) 10 2.0 (1.5-2.7) 19
eft ventricular function
Normal (LVEF 50%) 1 1
Mild impairment (LVEF 40%-50%) 1.0 (0.79-1.3) 0 0.75 (0.52-1.1) 3
Moderate impairment (LVEF 30%-40%) 0.38 (0.24-0.61) 16 0.49 (0.27-0.87) 6
Severe impairment (LVEF 30%) 0.27 (0.14-0.52) 15 0.18 (0.08-0.42) 16
roximal left anterior descending disease 2.2 (1.6-3.1) 22 1.9 (1.4-2.6) 17
eft main disease 6.6 (3.4-12) 34 12 (6.3-22) 60
o. of diseased arteries
1 1 1
2 2.1 (1.2-3.5) 8 1.4 (0.85-2.2) 2
3 3.9 (2.2-6.8) 23 5.4 (3.2-8.9) 43
otal occlusions
0 1 1
1 0.69 (0.52-0.91) 7 1.3 (0.93-1.8) 2
2 0.56 (0.36-0.87) 7 1.1 (0.67-1.9) 0
3 1.0 (0.60-1.8) 0 0.42 (0.21-0.87) 6
ype C lesions
0 1
1 0.87 (0.59-1.3) 0
2 0.73 (0.45-1.2) 2
3 0.40 (0.24-0.66) 12
006 The Journal of Thoracic and Cardiovascular Surgery ● November 2006
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CDreserved left ventricular function who had not undergone
rior coronary revascularization, provided lesions were suit-
ble for treatment. Coronary surgery was preferred over PCI
n patients with multivessel or left main disease, as well as
n those with concomitant valvular heart disease, provided a
ufficient number of lesions were suitable for CABG. These
hoices are coherent with the 1999 and 2002 guidelines to a
able 3. Continued
PCI vs medical
Odds ratio
(95% CI)* 2
esions suitable for PCI
0 1
1 28 (20-41) 308
2 35 (22-56) 232
3 41 (24-69) 189
esions suitable for CABG
0 1
1 0.74 (0.51-1.1) 3
2 0.52 (0.33-0.80) 9
3 0.26 (0.17-0.41) 34
dds ratios are adjusted for all variables that remained significant in mult
nal multivariable model. PCI, Percutaneous coronary intervention; CABG
anadian Cardiovascular Society; LVEF, left ventricular ejection fraction.
Odds ratio 1: increased preference for CABG rather than medical trea
Figure 1. Expected versus observed proportions of pa
within deciles of expected proportions, which are
Expected proportion of patients with a physician’s pref
than medical treatment. Middle, Expected proportion o
bypass grafting (CABG) rather than medical treatment
preference for CABG rather than PCI.
The Journal of Thoracicarge extent. There were, however, some intriguing varia-
ions between the guidelines and the routine practice that is
eflected in this survey. Impaired left ventricular function
as associated with an increased preference for medical
reatment. This contrasts with guidelines that recommend
oronary revascularization for most patients with multives-
el disease, especially those with abnormal left ventricular
Intended treatment
CABG vs medical CABG vs PCI
Odds ratio
(95% CI)† 2
Odds ratio
(95% CI)‡ 2
1 1
0.55 (0.36-0.85) 7 0.03 (0.02-0.05) 150
0.46 (0.28-0.75) 10 0.01 (0.01-0.02) 185
0.40 (0.24-0.66) 13 0.01 (0.01-0.02) 185
1 1
5.1 (2.8-9.4) 27 4.7 (2.3-9.4) 19
13 (6.9-23) 67 27 (13-56) 77
36 (20-66) 136 113 (53-239) 152
ble analysis. 2 represents the contribution of the variable at hand in the
onary artery bypass grafting; NYHA, New York Heart Association; CCS,
s ratio 1: increased preference for PCI rather than medical treatment.
. ‡Odds ratio 1: increased preference for CABG rather than PCI.
with a physician’s preference for specific treatment
d on multivariable logistic regression models. Left,
ce for percutaneous coronary intervention (PCI) rather
ents with a physician’s preference for coronary artery
t, Expected proportion of patients with a physician’sivaria
, cor
*Oddtients
base
eren
f pati
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A
CDunction.4 Indeed, randomized trials comparing CABG w
edical treatment in multivessel disease demonstrated a
ignificant improvement in symptoms, as well as a signifi-
ant mortality reduction during long-term follow-up in fa-
or of revascularization treatment, regardless of left ven-
ricular function.11 There are only a few randomized tr
omparing PCI versus medical treatment, but guidelines
peculate that patients with an intermediate-to-large myo-
ardium at risk (such as those with 2-vessel disease and a
roximal LAD lesion) will profit as much from percutane-
us transluminal coronary angioplasty as CABG. The ratio-
ale behind the deviation from the guidelines that we ob-
erved is not entirely clear. In fact, the interpretation of our
ata might be hampered by the heterogeneous nature of the
edically treated patients. In 45% of patients selected for
edical treatment, physicians reported a low-risk natural
istory as their main motivation behind their choice (T
). On the other hand, in 16% of patients, medical trea
as chosen because of a suspected high risk of periopera-
ive complications.
Patients with a prior history of CABG were much more
ften selected for medical treatment, independent of the
everity of anginal symptoms, the extent of coronary dis-
ase, and the number of lesions suitable for PCI or CABG.
linical trials comparing redo CABG versus medical treat-
ent in stable angina are lacking, as are trials comparing
edo CABG with PCI. The fact that physicians have been
ducated with the principle “primum non nocere” (“first do
o harm,” “better safe than sorry”) might therefore partly
xplain our findings.
It is interesting that diabetes was not associated with more
requent preference for CABG. Because large-scale random-
zed trials are lacking, it is still unclear whether optimal med-
cal management or revascularization should be preferred in
he general population of patients with stable angina and dia-
etes. The ongoing Bypass Angioplasty Revascularization In-
able 4. Reasons for choosing medical treatment only
eason (not exclusive)
Percentage of
patients
eneral condition of the patient not suitable
for PCI
13
eneral condition of the patient not suitable
for CABG
13
ow-risk natural history 45
ery high-risk procedure 16
ardiac contraindication 6
essels not suitable for PCI or CABG 49
atient refused PCI 4
atient refused CABG 9
CI, Percutaneous coronary intervention; CABG, coronary artery bypass
rafting.estigation 2 Diabetes trial, in which diabetic patients will be f
008 The Journal of Thoracic and Cardiovascular Surgery ● Novt
andomly allocated to aggressive medical management, target-
ng at optimal glycemic and metabolic control, or revascular-
zation, might help to solve this “burgeoning dilemma,” as the
nvestigators call it.16
imitations
ur study has several limitations that should be acknowl-
dged. First, the EHS surveys were conducted mainly in
ospital settings with liberal access to coronary revascular-
zation facilities. It is known that the availability of specific
edical resources, including coronary revascularization, de-
reases the threshold for its use.17
Second, our sample only represents a small fraction of all
atients admitted to catheterization laboratories throughout
urope during the study period, and one might question its
epresentativeness for the entire population. It is well known
hat decision processes might vary regionally, as well as
etween hospitals within a geographic region. Unfortu-
ately, we were not able to study these phenomena because
f the fact that there were too few participating hospitals
ithin meaningful regions and too few patients per hospital
the average number of patients per hospital was 23).
Third, patients were only enrolled in the EHS-CR once
he presence of coronary disease had been established by
eans of angiography. Obviously, there are many patients
ith stable angina without recent documentation of the
oronary anatomy who were not studied.
Fourth, no core laboratory analysis was performed of the
ualifying coronary angiogram. Consequently, detailed an-
tomic information that might have influenced treatment
ecisions was lacking.
Finally, the present data have been acquired before clin-
cal availability of drug-eluting stents. To what extent the
vailability of these devices will introduce a change in
ractice and treatment strategy will be examined in a new
urvey. Therefore the current results will serve as a bench-
ark for the evaluation of the effect of drug-eluting stents
n the practice of revascularization.
onclusions
n the hospitals that participated in the EHS-CR, treatment
ecisions in patients with stable coronary artery disease
ere largely in agreement with current guidelines. Most
mportant deviations between guideline recommendations
nd clinical practice patterns were seen in patients with
xtensive coronary disease, those with impaired left ven-
ricular function, and those with diabetes. The EHS-CR also
evealed that treatment decisions in patients with stable
oronary artery disease are determined by multiple factors.
nterestingly, several of these factors were exclusion criteria
n clinical trials that have been conducted in these patients,
ncluding prior revascularization, left main disease, renal
ailure, and heart failure. Thus to improve evidence-based
ember 2006
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CDedicine, guidelines would need to account for this and
ncorporate specific recommendations regarding the best
are for these specific patient subgroups.
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